Intent to Harm

Evidence of conspiracy to commit mass murder by the pharma manufacturers, US Department of Defense/HHS and other governments

Sasha Latypova, 2022

https://sashalatypova.substack.com

https://www.bitchute.com/channel/7dNrFbLeGSev/

TrialSiteNews.com



Summary of All Evidence => Intent to Harm

- **Toxic by Design:** Mechanisms of injury designed into C-19 injections
- **No Safety:** Horrific death and injury toll (VAERS, vSAFE, Eudravigilance, Yellow Card, etc => millions of reports)
- **No Efficacy:** negative efficacy 3+ months after injections
- **Bad Manufacturing:** Highly variable production, non-compliant with cGMP, no enforcement of cGMP by any agency
- **Malignant Policy Worldwide:** Government lies, cover-up, gaslighting of the injured, prosecution of dissent and whistleblowers, collusion with media, perverse financing of the above

WHY No Action By the Regulators or Courts?

Pseudo-Legalization of EUA-Covered "Military Countermeasures". Most Recent Relevant Legislation Includes:

Emergency Use Authorization (1997 Clinton) – Get rid of the FDA "safety & efficacy" regs under EUA

+

Other Transaction Authority (2015 Obama) – Enable DOD to order undisclosed "military prototypes" from pharma

↓

PREP Act and "Public Health Emergency" 2020 (Trump), continued by Biden to date

Law research by Katherine Watt, Bailiwick News on Substack

Use of EUA Countermeasures is NOT a Clinical Investigation:

- 21 USC 360bbb-3(k): **use** of EUA-covered medical countermeasure (MCM) products, once designated as such by the Secretary of Health and Human Services (March 10, 2020, retroactive to February 4, 2020) "**shall not be considered to constitute a clinical investigation.**" 21 USC 360bbb-3(k). EUA law, adopted 1997 and amended 2003, 2004, 2005, 2013, 2017.
- Countermeasures are NOT pharmaceutical products, NOT regulated by the FDA.

Research by Katherine Watt

"Countermeasures" Deployed at HHS Secretary's Discretion Are NOT Required to Meet Any Standards

Congressional amendments to the 1938 FD&C Act and the 1944 PHS Act had eliminated federal regulatory standards for production and use of products designated by the FDA for "emergency use" during an HHS-declared, HHS-maintained "public health emergency."

21 USC 360bbb-3(c) "Criteria for Issuance of Authorization": the law provides that the HHS Secretary may issue emergency use authorizations if he/she concludes:

- that, based on the totality of scientific evidence available to the Secretary, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that—
- (A) the product may be effective in diagnosing, treating, or preventing—
  - (i) such disease or condition; or
  - (ii) a serious or life-threatening disease or condition caused by a product authorized under this section, approved or cleared under this chapter, or licensed under section 351 of the Public Health Service Act [42 U.S.C. 262], for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and
- (B) the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable;

DOD and Pfizer agents had means, motive and opportunity, through OTA contracts to ensure that no evidence capable of interfering with the HHS Secretary and FDA regulatory officials (Azar/Kadlec/Gruber) EUA declarations would ever become available

Research by Katherine Watt

"Vaccine Development and Approval": performance art to convince the public

- Explains the use of the word "demonstration" in DOD contracts for vaccines
- Clinical trials were not ordered by DOD/HHS - not possible for countermeasures
- cGMP compliance was not ordered - not possible for countermeasures
- Legally there are no clinical trial subjects or investigators, and no informed consent

FDA leadership are impersonating the regulators and lying to the public – they have no authority to regulate countermeasures

National Security Council (NSC) in Charge of Covid Policy (Not HHS)

- The NSC is an executive forum for foreign policy and national security and does not include public health-related agencies.
- Regular attendees (both statutory and non-statutory) are:
  - Vice President
  - Secretary of State
  - Secretary of the Treasury
  - Secretary of Defense
  - Assistant to the President for National Security Affairs.
  - Chairman of the Joint Chiefs of Staff is the statutory military advisor to the Council
  - Director of National Intelligence is the intelligence advisor

Decisional Role



Pandemic response org chart, from p. 9 of ***Pandemic Crisis Action Plan- Adapted, 2020 (PanCAP-A)***, showing the NSC solely responsible for Covid policy

Figurehead Role

Information Control /Propaganda Role

Why is FEMA (not HHS) Lead Federal Agency?

- *"On March 13, 2020, President Donald J. Trump declared a nationwide emergency under the Robert T. Stafford Disaster Relief and Emergency Assistance Act (the Stafford Act, P.L. 93-288 as amended), authorizing assistance administered by the Federal Emergency Management Agency (FEMA). Five days later, the President notified then-FEMA Administrator Peter Gaynor that the agency would assume leadership of the federal pandemic response effort—the first known instance of FEMA serving in such a role for a public health incident."*

"FEMA's Role in the Covid-19 Pandemic Response"
https://crsreports.congress.gov/product/pdf/R/R47048

Not in charge: Pharma companies ($$$$)

In charge: NSC, DOD, BARDA



Who is REALLY developing and manufacturing these injections?

As of October 20, 2020

OWS/BARDA Vaccine Manufacturing Portfolio



Mfg = ≥100M doses

BARDA'S Early Investments Paved the Way for Federal COVID-19 Response Success





2021

CT REGENERON
casirivimab & Imdevimab (SARS-CoV-2 specific mAbs) & Mfg.
Demo
EUA

CT Roche Genentech
Anti-IL6R mAb (Actemra®)
EUA

CT
Convalescent Plasma
EUA

CT Lilly
Bamlanivimab & Etesevimab
EUA

CT moderna
mRNA-1273 Commercial Scale Mfg
EUA

CT Johnson&Johnson janssen
Ad26 COVID-19 Vaccine Mfg
Demo
EUA

CT AstraZeneca
AZD1222 (ChAdOx1) R&D and Commercial Scale Mfg

CT gsk SANOFI PASTEUR
Recombinant Protein + AS03 Adjuvant Mfg. Demo

CT Pfizer
BNT162 (mRNA) Commercial Scale Mfg (Comirnaty)
BLA

Accelerating Development of Safe and Effective Vaccines



- Platform Technologies
- Multiple Candidates
- Large Scale Manufacturing in Parallel with Clinical Trials
- Large Phase III Trials

- Violation of cGMP (CFR Title 21*)
- Not possible to manufacture <u>safe</u> products before safety is properly tested
- "Platforms" do not exempt each product from full safety testing requirements

*https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations



Source: BARDA "Industry Day" webinar, November 2022

by KEI. ***Linked herein is a comprehensive list of all US government COVID-19-related contracts obtained by KEI via FOIA.***

- **Advanced Technology International (ATI) – Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government**.
  - DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.
  - DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
- **Aerpio – respiratory condition treatment**.
  - DOD-Aerpio Statement of Work W81XWH1590001.
  - DOD-Aerpio Project Approval Letter W81XWH1590001. July 28, 2020.
- **Altimmune – therapeutic.**
  - DoD-Altimmune Project Approval Letter W81XWH159001. June 17, 2020.
  - DoD-Altimmune Statement of Work W81XWH159001.
  - DoD-Altimmune Revised Project Approval Letter (3) W81XWH159001. February 3, 2021.
  - DoD-Altimmune Revised Project Approval Letter (2) W81XWH159001. December 15, 2020.
- **America's Blood Center – convalescent plasma**.
  - HHS/ASPR/BARDA-America's Blood Center Contract 75A50120000094 (includes Mods 1-8). April 17, 2020.
  - DOD-America's Blood Centers Contract W911QY2190006. October 30, 2020.
- **ANP Technologies – diagnostics.**
  - DoD-ANP Technologies Contract W911QY20D0019 (includes Mods 1-3). May 29, 2020.
  - DOD-ANP Technologies Supply Order W911QY20D0019 (includes Mods 1-3). June 2, 2020.
  - DOD-ANP Technologies Supply Order W911QY20P0141 (includes Mod 1). April 17, 2020.
- **AstraZeneca – vaccine.**
  - HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.
  - HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.
- **AstraZeneca – vaccine.**
  - DoD-AstraZeneca Other Transaction Authority Agreement W15QKN2191003. October 28, 2020.
- **AstraZeneca – prophylactic monoclonal antibody.**
  - DOD-AstraZeneca Contract W911QY2190001 (includes Mods 1, 2, 3, and 5). October 9, 2020.
- **AstraZeneca – therapeutic.**
  - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020.
  - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020. (Version obtained by FOIA)
- **Atlantic Diving Supply – no-contact thermometers**.
  - DOD-Atlantic Diving Supply Contract W911QY18D0019. September 16, 2020.
- **Beckman Coulter – diagnostic-related.**
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078. September 30, 2019.
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078-P00001. May 15, 2020.
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50120C00189. September 28, 2020.
- **Biofire Defense – diagnostics.**
  - DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0271. April 24, 2020.
  - DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0171 (includes Mods 1-2). May 23, 2020.
  - DOD-Biofire Defense Supply Order W911QY20F0196 and W911QY20F0165 Contract W911QY13D0080 (includes Mod 1 of W911QY20F0196). April 17, 2020.
- **BCG Federal Corp – COVID-19-related support services.**

- All contracts from DOD via ATI "management company", not directly with government
- Robert Kadlec (ASPR Secretary under Trump) personally controlled $$$ contracts.

Full list available at https://www.keionline.org/covid-contracts